Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors

Nuclear Medicine and Biology

Volumn 45, Issue , 2017, Pages 15-21

  Honarvar, Hadis ^a   Müller, Cristina ^b   Cohrs, Susan ^b   Haller, Stephanie ^b   Westerlund, Kristina ^c   Karlström, Amelie Eriksson ^c   van der Meulen, Nicholas P ^b,d,e   Schibli, Roger ^b,d,e   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ETH Zurich   (Switzerland)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^d PAUL SCHERRER INSTITUTE   (Switzerland)

^e ETH ZURICH   (Switzerland)

Author keywords

44Sc; Affibody molecule; DOTA; HER2; PET imaging; ZHER2:2891

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; RADIOISOTOPE; SCANDIUM 44; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; RECOMBINANT PROTEIN; SCANDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PLASMA CLEARANCE; PROTEIN BINDING; PROTEIN EXPRESSION; RADIOCHEMISTRY; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTOPE LABELING; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; SCANDIUM; TISSUE DISTRIBUTION;

EID: 84994908259     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2016.10.004     Document Type: Article

References (49)

1. [1] Weiner, L.M., Surana, R., Wang, S., Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10 (2010), 317-327.
2. [2] Mankoff, D.A., Molecular imaging to select cancer therapy and evaluate treatment response. J Nucl Med Mol Imaging 53 (2009), 181-192.
3. [3] Tolmachev, V., Stone-Elander, S., Orlova, A., Radiolabelled receptor tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 1 (2010), 992-1000.
4. [4] Wu, A.M., Olafsen, T., Antibodies for molecular imaging of cancer. Cancer J 14 (2008), 191-197.
5. [5] Wester, H.J., Kessler, H., Molecular targeting with peptides or peptide-polymer conjugates: just a question of size?. J Nucl Med 46 (2005), 1552-1560.
6. [6] Lee, S., Xie, J., Chen, X., Peptide-based probes for targeted molecular imaging. Biochemistry 49 (2010), 1364-1376.
7. [7] Miao, Z., Levi, J., Cheng, Z., Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 41 (2011), 1037-1047.
8. [8] Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., Frejd, F.Y., Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584 (2010), 2670-2680.
9. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 50 (2009), 417-425.
10. [10] Ahlgren, S., Tolmachev, V., Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 11 (2010), 581-589.
11. [11] Tolmachev, V., Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 14 (2008), 2999-3019.
12. [12] Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367 (2012), 1783-1791.
13. [13] Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor-2 positive metastatic breast cancer administered as first line treatment: the M77001 study group. J Clin Oncol 9 (2001), 4265-4274.
14. [14] Arteaga, C.L., Sliwkowski, M.X., Kent Osborne, C., Perez, E.A., Puglisi, F., Gianni, L., Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9 (2012), 16-32.
15. [15] Wilking, U., Karlsson, E., Skoog, L., Hatschek, T., Lidbrink, E., Elmberger, G., et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 125 (2011), 553-561.
16. [16] Houssami, N., Macaskill, P., Balleine, R.L., Bilous, M., Pegram, M.D., HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat 129 (2011), 659-674.
17. [17] Aurilio, G., Disalvatore, D., Pruneri, G., Bagnardi, V., Viale, G., Curigliano, G., et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 50 (2014), 277-289.
18. 68Ga-labeled Affibody molecules. J Nucl Med 51 (2010), 892-897.
19. 68Ga]ABY-025 Affibody PET/CT. Theranostics 6 (2016), 262-271.
20. 44Sc. Appl Radiat Isot, 109, 2016, 314318.
21. 44Sc-DOTA-folate conjugate. J Nucl Med 54 (2013), 2168-2174.
22. 44Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET. Appl Radiat Isot 110 (2016), 129-133.
23. 44Sc for labeling of DOTA- and NODAGA- functionalized peptides: preclinical in vitro and in vivo investigations. EJNMMI Radiopharm Chem, 1, 2016, 8.
24. 44Sc-DOTA-puromycin. Mol Imaging Biol 15 (2013), 79-86.
25. [25] Singh, A., Baum, R., Klette, I., van der Meulen, N., Müller, C., Türler, A., et al. Scandium-44 DOTATOC PET/CT: first in-human molecular imaging of neuroendocrine tumors and possible perspectives for theranostics. J Nucl Med, 56, 2015, 267.
26. 44Sc: an attractive isotope for peptide-based PET imaging. Mol Pharm 11 (2014), 2954-2961.
27. 44m/44Sc and experimental evidence of the feasibility of an in vivo PET generator. Nucl Med Biol 41 (2014), 36-43.
28. 44Sc generator system. Curr Radiopharm 5 (2012), 187-201.
29. 90Y-DOTA for potential application in intra-vascular radionuclide therapy. Appl Radiat Isot 57 (2002), 313-318.
30. 47Sc for radionuclide tumor therapy in mice. J Nucl Med 55 (2014), 1658-1664.
31. 44Sc-labeled cetuximab fab fragment. Bioconjug Chem 25 (2014), 2197-2204.
32. [32] Westerlund, K., Honarvar, H., Norrström, E., Strand, J., Mitran, B., Orlova, B., et al. Increasing the net negative charge by replacement of DOTA chelator with DOTAGA improves the biodistribution of radiolabeled second-generation synthetic Affibody molecules. Mol Pharm 13 (2016), 1668-1678.
33. [33] Yu, D., Wolf, J.K., Scanlon, M., Price, J.E., Hung, M.C., Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53 (1993), 891-898.
34. 111In-labelled analogue. Eur J Nucl Med Mol Imaging 37 (2010), 1356-1367.
35. 44Sc: from bench to bedside. Nucl Med Biol 42 (2015), 745-751.
36. 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 23 (2008), 435-442.
37. 111In-labeled counterparts. PLoS One, 8, 2013, 70028.
38. 111In- labeled conjugates. Mol Imaging 13 (2014), 1-12.
39. [39] Altai, M., Varasteh, Z., Andersson, K., Eek, A., Boerman, O., Orlova, A., In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. Cancer Biother Radiopharm 28 (2013), 187-195.
40. 111In-ABY-025 Affibody molecule. J Nucl Med 55 (2014), 730-735.
41. [41] Heppeler, A., Froidevaux, S., Mäcke, H.R., Jermann, E., Béhé, M., Powell, P., et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor rmediated internal radiotherapy. Chem A Eur J 5 (1999), 1974-1981.
42. 111In labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 35 (2008), 1507-1515.
43. 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med 52 (2011), 1110-1118.
44. 44Sc a potential radionuclide for PET?. Appl Radiat Isot 70 (2012), 2669-2676.
45. 2]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol 16 (2014), 255-263.
46. [46] Strand, J., Varasteh, Z., Eriksson, O., Abrahmsen, L., Orlova, A., Tolmachev, V., Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo. Mol Pharm 11 (2014), 3957-3964.
47. [47] Price, E.W., Orvig, C., Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev 43 (2014), 260-290.
48. [48] Majkowska-Pilip, A., Bilewicz, A., Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem 105 (2011), 313-320.
49. [49] Eckelman, W.C., Kilbourn, M.R., Mathis, C.A., Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems!. Nucl Med Biol 36 (2009), 235-237.